Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AX4H
|
|||
| Drug Name |
GSK3179106
|
|||
| Synonyms |
RET Kinase inhibitor 1; SCHEMBL16055027; CHEMBL3355009; IDXKJSSOUXWLDB-UHFFFAOYSA-N; CS-7799; HY-100459; 1627856-64-7; 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
Click to Show/Hide
|
|||
| Indication | Inflammatory bowel disease [ICD-11: DD72; ICD-10: K50-K52] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline Research Triangle Park, NC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H21F4N3O4
|
|||
| Canonical SMILES |
CCOC1=CC(=O)NC=C1C2=CC(=C(C=C2)CC(=O)NC3=NOC(=C3)C(C)(C)C(F)(F)F)F
|
|||
| InChI |
1S/C22H21F4N3O4/c1-4-32-16-9-19(30)27-11-14(16)12-5-6-13(15(23)7-12)8-20(31)28-18-10-17(33-29-18)21(2,3)22(24,25)26/h5-7,9-11H,4,8H2,1-3H3,(H,27,30)(H,28,29,31)
|
|||
| InChIKey |
IDXKJSSOUXWLDB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1627856-64-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-Ret (RET) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Endocytosis | |||
| Pathways in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| Pathway Interaction Database | Signaling events regulated by Ret tyrosine kinase | |||
| Posttranslational regulation of adherens junction stability and dissassembly | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Dopaminergic Neurogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.